These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1002 related items for PubMed ID: 10544913

  • 1. Laboratory testing for von Willebrand's disease: an assessment of current diagnostic practice and efficacy by means of a multi-laboratory survey. RCPA Quality Assurance Program (QAP) in Haematology Haemostasis Scientific Advisory Panel.
    Favaloro EJ, Smith J, Petinos P, Hertzberg M, Koutts J.
    Thromb Haemost; 1999 Oct; 82(4):1276-82. PubMed ID: 10544913
    [Abstract] [Full Text] [Related]

  • 2. Laboratory diagnosis of von Willebrand's disorder: quality and diagnostic improvements driven by peer review in a multilaboratory test process.
    Favaloro EJ, Bonar R, Kershaw G, Sioufi J, Hertzberg M, Street A, Lloyd J, Marsden K, RCPA QAP in Haematology.
    Haemophilia; 2004 May; 10(3):232-42. PubMed ID: 15086320
    [Abstract] [Full Text] [Related]

  • 3. 2B or not 2B? Disparate discrimination of functional VWF discordance using different assay panels or methodologies may lead to success or failure in the early identification of type 2B VWD.
    Favaloro EJ, Bonar R, Meiring M, Street A, Marsden K, RCPA QAP in Haematology.
    Thromb Haemost; 2007 Aug; 98(2):346-58. PubMed ID: 17721617
    [Abstract] [Full Text] [Related]

  • 4. Laboratory diagnosis of von Willebrand disorder: use of multiple functional assays reduces diagnostic error rates.
    Favaloro EJ, Bonar R, Kershaw G, Sioufi J, Thom J, Baker R, Hertzberg M, Street A, Lloyd J, Marsden K, Royal College Of Pathologists Of Australasia Quality Assurance Program In Haematology.
    Lab Hematol; 2005 Aug; 11(2):91-7. PubMed ID: 16024332
    [Abstract] [Full Text] [Related]

  • 5. Reducing errors in identification of von Willebrand disease: the experience of the royal college of pathologists of australasia quality assurance program.
    Favaloro EJ, Bonar R, Kershaw G, Sioufi J, Baker R, Hertzberg M, Street A, Marsden K.
    Semin Thromb Hemost; 2006 Jul; 32(5):505-13. PubMed ID: 16862524
    [Abstract] [Full Text] [Related]

  • 6. Lower limit of assay sensitivity: an under-recognised and significant problem in von Willebrand disease identification and classification.
    Favaloro EJ, Bonar R, Marsden K.
    Clin Lab Sci; 2008 Jul; 21(3):178-83. PubMed ID: 18678140
    [Abstract] [Full Text] [Related]

  • 7. Laboratory assessment as a critical component of the appropriate diagnosis and sub-classification of von Willebrand's disease.
    Favaloro EJ.
    Blood Rev; 1999 Dec; 13(4):185-204. PubMed ID: 10741895
    [Abstract] [Full Text] [Related]

  • 8. Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays?
    Favaloro EJ, Thom J, Patterson D, Just S, Dixon T, Koutts J, Baccala M, Rowell J, Baker R.
    Thromb Res; 2009 Apr; 123(6):862-8. PubMed ID: 19064279
    [Abstract] [Full Text] [Related]

  • 9. Comparative study on collagen-binding enzyme-linked immunosorbent assay and ristocetin cofactor activity assays for detection of functional activity of von Willebrand factor.
    Turecek PL, Siekmann J, Schwarz HP.
    Semin Thromb Hemost; 2002 Apr; 28(2):149-60. PubMed ID: 11992238
    [Abstract] [Full Text] [Related]

  • 10. An external quality assessment program for von Willebrand factor laboratory analysis: an overview from the European concerted action on thrombosis and disabilities foundation.
    Meijer P, Haverkate F.
    Semin Thromb Hemost; 2006 Jul; 32(5):485-91. PubMed ID: 16862521
    [Abstract] [Full Text] [Related]

  • 11. Laboratory diagnosis and molecular classification of von Willebrand disease.
    Gadisseur A, Hermans C, Berneman Z, Schroyens W, Deckmyn H, Michiels JJ.
    Acta Haematol; 2009 Jul; 121(2-3):71-84. PubMed ID: 19506352
    [Abstract] [Full Text] [Related]

  • 12. Assessment of current diagnostic practice and efficacy in testing for von Willebrand's disorder: results from the second Australasian multi-laboratory survey.
    Favaloro EJ, Thom J, Baker R, Australasian Society for Thrombosis and Haemostasis (ASTH) Emerging Technologies Group.
    Blood Coagul Fibrinolysis; 2000 Dec; 11(8):729-37. PubMed ID: 11132651
    [Abstract] [Full Text] [Related]

  • 13. Von Willebrand factor collagen-binding (activity) assay in the diagnosis of von Willebrand disease: a 15-year journey.
    Favaloro EJ.
    Semin Thromb Hemost; 2002 Apr; 28(2):191-202. PubMed ID: 11992242
    [Abstract] [Full Text] [Related]

  • 14. Discrimination of von Willebrands disease (VWD) subtypes: direct comparison of von Willebrand factor:collagen binding assay (VWF:CBA) with monoclonal antibody (MAB) based VWF-capture systems.
    Favaloro EJ, Henniker A, Facey D, Hertzberg M.
    Thromb Haemost; 2000 Oct; 84(4):541-7. PubMed ID: 11057847
    [Abstract] [Full Text] [Related]

  • 15. von Willebrand disease in a pediatric-based population--comparison of type 1 diagnostic criteria and use of the PFA-100 and a von Willebrand factor/collagen-binding assay.
    Dean JA, Blanchette VS, Carcao MD, Stain AM, Sparling CR, Siekmann J, Turecek PL, Lillicrap D, Rand ML.
    Thromb Haemost; 2000 Sep; 84(3):401-9. PubMed ID: 11019962
    [Abstract] [Full Text] [Related]

  • 16. Development of an ELISA method for testing VWF ristocetin cofactor activity with improved sensitivity and reliability in the diagnosis of von Willebrand disease.
    Zhao Y, Gu Y, Ji S, Yang J, Yu Z, Ruan C.
    Eur J Haematol; 2012 May; 88(5):439-45. PubMed ID: 22268616
    [Abstract] [Full Text] [Related]

  • 17. Collagen binding assay for von Willebrand factor (VWF:CBA): detection of von Willebrands Disease (VWD), and discrimination of VWD subtypes, depends on collagen source.
    Favaloro EJ.
    Thromb Haemost; 2000 Jan; 83(1):127-35. PubMed ID: 10669166
    [Abstract] [Full Text] [Related]

  • 18. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A, Berneman Z, Schroyens W, Michiels JJ.
    Acta Haematol; 2009 Jan; 121(2-3):128-38. PubMed ID: 19506359
    [Abstract] [Full Text] [Related]

  • 19. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
    Favaloro EJ, Lloyd J, Rowell J, Baker R, Rickard K, Kershaw G, Street A, Scarff K, Barrese G, Maher D, McLachlan AJ.
    Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
    [Abstract] [Full Text] [Related]

  • 20. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ, van Vliet HH, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van der Velden A, Budde U.
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 51.